What is SciFluor Life Sciences?
SciFluor Life Sciences is a biopharmaceutical company focused on creating proprietary, best-in-class drugs targeting significant unmet medical needs. The company leverages well-understood biological pathways to develop treatments in key therapeutic areas, including ophthalmology, neuroscience, and fibrotic diseases. Their lead clinical candidate, SF0166, is an eye drop formulation designed for the treatment of back-of-the-eye diseases, representing a crucial step in their pipeline development.
How much funding has SciFluor Life Sciences raised?
SciFluor Life Sciences has raised a total of $44.6M across 2 funding rounds:
Series A
$30M
Series B
$14.6M
Series A (2015): $30M with participation from Allied Minds and Woodford Investment Management
Series B (2021): $14.6M, investors not publicly disclosed
Key Investors in SciFluor Life Sciences
Allied Minds
Allied Minds plc is an intellectual property commercialization company, focusing on bringing new technologies to market.
Woodford Investment Management
Woodford Investment Management is a UK-based financial services firm involved in managing investment funds, with a focus on providing managed investment solutions.
What's next for SciFluor Life Sciences?
The recent major strategic investment signals a pivotal phase for SciFluor Life Sciences, likely enabling the acceleration of its clinical development programs and the expansion of its research initiatives. This capital infusion is expected to support the progression of SF0166 through further clinical trials and potentially facilitate the advancement of other pipeline candidates. The company's focus on established pathways suggests a strategy aimed at de-risking drug development, positioning them for future growth and potential partnerships within the pharmaceutical sector.
See full SciFluor Life Sciences company page
